MedPath

Phase I/II study of arterial infusion of 5-fluorouracil combined with systemic gemcitabine for unresectable pancreatic cancer

Phase 1
Conditions
nresectable pancreatic cancer
Registration Number
JPRN-UMIN000000573
Lead Sponsor
ara Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
24
Inclusion Criteria

Not provided

Exclusion Criteria

1)distant metastaes except of liver and node 2)adequate drug distribution via celiac arterial infusion with alteration of pancreatic blood flow will not be achieved 3)Interstitial pneumonia in chest X-ray 4)active gastro-duodenal ulcer 5)Allergic reaction to iodine contrast material. 6)Infectious disease with fever over 38 degree Celcius or antibiotics required. 7)Pregnant or nursing. 8)Severe drug allergic reaction 9)The other severe complicated disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath